Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 2125-2143

  Daval, Sandrine B ^a,b   Valant, Céline ^a,c   Bonnet, Dominique ^a   Kellenberger, Esther ^a   Hibert, Marcel ^a   Galzi, Jean Luc ^a   Ilien, Brigitte ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b IQVIA   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; AC 260584; AC 42; AE 51090; GALLAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; NORCLOZAPINE; RHODAMINE B; UNCLASSIFIED DRUG; VU 0357071;

ALLOSTERISM; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN;

ALLOSTERIC REGULATION; CALCIUM; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR PROBES; PIPERIDINES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M1; RECOMBINANT FUSION PROTEINS; RHODAMINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858054143     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201348t     Document Type: Article

References (62)

1. Eglen, R. M. Muscarinic receptor subtype pharmacology and physiology Prog. Med. Chem. 2005, 43, 105-136
2. Wess, J.; Eglen, R. M.; Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development Nat. Rev. Drug Discovery 2007, 6, 721-733
3. Digby, G. J.; Shirey, J. K.; Conn, P. J. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol. BioSyst. 2010, 6, 1345-1354
4. Birdsall, N. J. M.; Lazareno, S. Allosterism at muscarinic receptors: ligands and mechanisms Mini-Rev. Med. Chem. 2005, 33, 523-543
5. De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Tränkle, C.; Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med. Res. Rev. 2010, 30, 463-549
6. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 14.1-14.51
7. Maillet, E. L.; Pellegrini, N.; Valant, C.; Bucher, B.; Hibert, M.; Bourguignon, J.-J.; Galzi, J.-L. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J. 2007, 21, 2124-2134
8. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods Mol. Pharmacol. 1988, 35, 187-194
9. Sur, C.; Mallorga, P. J.; Wittmann, M.; Jacobson, M. A.; Pascarella, D.; Williams, J. B.; Brandish, P. E.; Pettibone, D. J.; Scolnick, E. M.; Conn, P. J. N -Desmethylclozapine, an allosteric agonist at muscarinic M1 receptor, potentiates N -methyl- d -aspartate receptor activity Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13674-13679
10. Spalding, T. A.; Trotter, C.; Skjaerbaek, N.; Messier, T. L.; Currier, E. A.; Burstein, E. S.; Li, D.; Hacksell, U.; Brann, M. R. Discovery of an ectopic activation site on the M1 muscarinic receptor Mol. Pharmacol. 2002, 61, 1297-1302
11. Langmead, C. J.; Fry, V. A. H.; Forbes, I. T.; Branch, C. L.; Christopoulos, A.; Wood, M. D.; Herdon, H. J. Probing the molecular mechanism of interaction between 4- n -butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M1 receptor: direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 2006, 69, 236-246
12. Spalding, T. A.; Ma, J. N.; Ott, T. R.; Friberg, M.; Bajpai, A.; Risso Bradley, S.; Davis, R. E.; Brann, M. R.; Burstein, E. S. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N -desmethylclozapine: evidence for three distinct modes of receptor activation Mol. Pharmacol. 2006, 70, 1974-1983
13. Langmead, C. J.; Austin, N. E.; Branch, C. L.; Brown, J. T.; Buchanan, K. A.; Davies, C. H.; Forbes, I. T.; Fry, V. A. H.; Hagan, J. J.; Herdon, H. J.; Jones, G. A.; Jeggo, R.; Kew, J. N. C.; Mazzali, A.; Melarange, R. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 2008, 154, 1104-1115
14. Jones, C. K.; Brady, A. E.; Davis, A. A.; Xiang, Z.; Bubser, M.; Tantawy, M. N.; Kane, A. S.; Bridges, T. M.; Kennedy, J. P.; Bradley, S. R.; Peterson, T. E.; Ansari, M. S.; Baldwin, R. M. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 2008, 28, 10422-10433
15. Sams, A. G.; Hentzer, M.; Mikkelsen, G. K.; Larsen, K.; Bundgaard, C.; Plath, N.; Christofferson, C. T.; Bang-Andersen, B. Discovery of N -{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl} -2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and precognitive potential J. Med. Chem. 2010, 53, 6386-6397
16. Lebois, E. P.; Bridges, T. M.; Lewis, L. M.; Dawson, E. S.; Kane, A. S.; Xiang, Z.; Jadhav, S.; Yin, H.; Kennedy, J. P.; Meiler, J.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Weaver, C. D.; Lindsley, C. W. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system ACS Chem. Neurosci. 2010, 1, 104-121
17. Bradley, S. R.; Lameh, J.; Ohrmund, L.; Son, T.; Bajpai, A.; Nguyen, D.; Friberg, M.; Burstein, E. S.; Spalding, T. A.; Ott, T. R.; Schiffer, H. H.; Tabatabaei, A.; McFarland, K.; Davis, R. E.; Bonhaus, D. W. AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model Neuropharmacology 2010, 58, 365-373
18. Buchanan, K. A.; Petrovic, M. M.; Chamberlain, S. E. L.; Marrion, N. V.; Mellor, J. R. Facilitation of long-term potentiation by muscarinic M1 receptors is mediated by inhibition of SK channels Neuron 2010, 68, 948-963
19. Thomas, R. L.; Mistry, R.; Langmead, C. J.; Wood, M. D.; Challiss, R. A. J. G protein coupling and signalling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists J. Pharmacol. Exp. Ther. 2008, 327, 365-374
20. Thomas, R. L.; Langmead, C. J.; Wood, M. D.; Challiss, R. A. J. Contrasting effects of allosteric and orthosteric agonists on M1 muscarinic acetylcholine receptor internalization and down-regulation J. Pharmacol. Exp. Ther. 2009, 331, 1086-1095
21. Davis, A. A.; Heilman, C. J.; Brady, A. E.; Miller, N. R.; Fuerstenau-Sharp, M.; Hanson, B. J.; Lindsley, C. W.; Conn, P. J.; Lah, J. J.; Levey, A. I. Differential effects of allosteric M1 muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation ACS Chem. Neurosci. 2010, 1, 542-551
22. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relationships in G-protein coupled receptors Methods Neurosci. 1995, 25, 366-428
23. Lebon, G.; Langmead, C. J.; Tehan, B. G.; Hulme, E. C. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors Mol. Pharmacol. 2009, 75, 331-341
24. Avlani, V. A.; Langmead, C. J.; Guida, E.; Wood, M. D.; Tehan, B. G.; Herdon, H. J.; Watson, J. M.; Sexton, P. M.; Christopoulos, A. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor Mol. Pharmacol. 2010, 78, 94-104
25. Gregory, K. J.; Hall, N. E.; Tobin, A. B.; Sexton, P. M.; Christopoulos, A. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signalling bias J. Biol. Chem. 2010, 285, 7459-7474
26. Jacobson, M. A.; Kreatsoulas, C.; Pascarella, D. M.; O'Brien, J. A.; Sur, C. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2 H -benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site Mol. Pharmacol. 2010, 78, 648-657
27. Ilien, B.; Franchet, C.; Bernard, P.; Morisset, S.; Weill, C. O.; Bourguignon, J.-J.; Hibert, M.; Galzi, J.-L. Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties J. Neurochem. 2003, 85, 768-778
28. Ilien, B.; Glasser, N.; Clamme, J.-P.; Didier, P.; Piemont, E.; Chinnappan, R.; Daval, S. B.; Galzi, J.-L.; Mely, Y. Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process J. Biol. Chem. 2009, 284, 19533-19543
29. Vanover, K. E.; Veinbergs, I.; Davis, R. E. Antipsychotic-like behavioural effects and cognitive enhancement by a potent and selective muscarinic M1 receptor agonist, AC-260584 Behav. Neurosci. 2008, 122, 570-575
30. Astles, P. C.; Brealey, C.; Brown, T. J.; Facchini, V.; Handscombe, C.; Harris, N. V.; McCarthy, C.; McLay, I. M.; Porter, B.; Roach, A. G.; Sargent, C.; Smith, C.; Walsh, R. J. A. Selective endothelin A receptor antagonists: discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives J. Med. Chem. 1998, 41, 2732-2744
31. Ward, H. R.; Sherman, P. D. Carbonyl participation in the solvolysis of ketone derivatives. The observation and isolation of intermediates J. Am. Chem. Soc. 1968, 90, 3812-3817
32. Wustrow, D. J.; Wise, L. D. Coupling of arylboronic acids with a partially reduced pyridine derivative Synthesis 1991, 11, 993-995
33. Scott, W. J.; Pena, M. R.; Sward, K.; Stoessel, S. J.; Stille, J. K. Palladium-catalyzed olefination of vinyl triflates J. Org. Chem. 1985, 50, 2302-2308
34. Crisp, G. T.; Jiang, Y.-L.; Pullman, P. J.; De Savi, C. Elaboration of the side-chain of amino acid derivatives by palladium catalysed couplings Tetrahedron 1997, 53, 17489-17500
35. Berrée, F.; Michelot, G.; Le Corre, M. N -Boc ethyl oxamate: a new nitrogen nucleophile for use in Mitsunobu reactions Tetrahedron Lett. 1998, 39, 8275-8276
36. Bonnet, D.; Riche, S.; Loison, S.; Dagher, R.; Frantz, M. C.; Boudier, L.; Rahmeh, R.; Mouillac, B.; Haiech, J.; Hibert, M. Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin receptor ligand Chem.-Eur. J. 2008, 14, 6247-6254
37. Corrie, J. E. T.; Davis, C. T.; Eccleston, J. F. Chemistry of sulforhodamine-amine conjugates Bioconjugate Chem. 2001, 12, 186-194
38. Tahtaoui, C.; Parrot, I.; Klotz, P.; Guillier, F.; Galzi, J.-L.; Hibert, M.; Ilien, B. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor J. Med. Chem. 2004, 47, 4300-4315
39. Weill, C.; Galzi, J. L.; Chasserot-Golaz, S.; Goeldner, M.; Ilien, B. Functional characterization and potential applications for enhanced green fluorescent protein- and epitope-fused human M1 muscarinic receptors J. Neurochem. 1999, 73, 791-801
40. Lazareno, S.; Birdsall, N. J. M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors Mol. Pharmacol. 1995, 48, 362-378
41. Jakubik, J.; Bacakova, L.; El-Fakahany, E. E.; Tucek, S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors Mol. Pharmacol. 1997, 52, 172-179
42. Matsui, H. S.; Lazareno, S.; Birdsall, N. J. M. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis Mol. Pharmacol. 1995, 47, 88-98
43. 3H] scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site Mol. Pharmacol. 2000, 58, 194-207
44. Gharagozloo, P.; Lazareno, S.; Popham, A.; Birdsall, N. J. M. Allosteric interactions of quaternary strychnine and brucine derivatives with muscarinic acetylcholine receptors J. Med. Chem. 1999, 42, 438-445
45. 125I-Met35-oxidized muscarinic toxin 7 Mol. Pharmacol. 2006, 69, 1641-1651
46. Kostenis, E.; Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation Trends Pharmacol. Sci. 1996, 17, 280-283
47. Kurtenbach, E.; Curtis, C. A. M.; Pedder, E. K.; Aitken, A.; Harris, A. C. M.; Hulme, E. C. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation J. Biol. Chem. 1990, 265, 13702-13708
48. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 2011, 54, 4283-4311
49. Förster, T. Zwischenmolekulare energiewanderung und fluoreszenz Ann. Phys. (Leipzig) 1948, 2, 55-75
50. Lazareno, S.; Popham, A.; Birdsall, N. J. M. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors Mol. Pharmacol. 2002, 62, 1492-1505
51. Hulme, E. C.; Lu, Z. L.; Saldanha, J. W.; Bee, M. S. Structure and activation of muscarinic acetylcholine receptors Biochem. Soc. Trans. 2003, 31, 29-34
52. Peng, J. Y.; Vaidehi, N.; Hall, S. E.; Goddard, W. A The predicted 3D structure of the human M1 muscarinic acetylcholine receptor with agonist and antagonist bound ChemMedChem 2006, 1, 878-890
53. Jakubik, J.; El-Fakahany, E. E.; Tucek, S. Evidence for a tandem two-site model of ligand binding to muscarinic acetylcholine receptors J. Biol. Chem. 2000, 275, 18836-18844
54. Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors Curr. Neuropharmacol. 2007, 5, 157-167
55. 3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors Mol. Pharmacol. 2003, 64, 180-190
56. Palanché, T.; Ilien, B.; Zoffmann, S.; Reck, M.-P.; Bucher, B.; Edelstein, S.; Galzi, J.-L. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states J. Biol. Chem. 2001, 276, 34853-34861
57. 7/3-phth) at cloned muscarinic acetylcholine receptors Biochem. Pharmacol. 1999, 57, 171-179
58. Valant, C.; Gregory, K. J.; Hall, N. E.; Scammels, P. J.; Lew, M. J.; Sexton, P. M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J. Biol. Chem. 2008, 283, 29312-29321
59. Narlawar, R.; Lane, J. R.; Doddareddy, M.; Lin, J.; Brussee, J.; Ijzerman, A. P. Hybrid ortho/allosteric ligands for the adenosine A1 receptor J. Med. Chem. 2010, 53, 3028-3037
60. Antony, J.; Kellershohn, K.; Mohr-Andrä, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Tränkle, C.; Kostenis, E.; Christopoulos, A.; Höltje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 2009, 23, 442-450
61. Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic hybrids. Going hybrid at GPCRs Mol. Interventions 2009, 9, 125-135
62. Molecular Probes. http://www.probes.com/handbook/.